UKRI Translation: MRC Impact Acceleration Award 2026: £50,000 to £300,000 for One High-Risk Development Step Toward a New Medicine, Device, or Diagnostic — Applications Close 11 November 2026

UKRI Translation: MRC Impact Acceleration Award 2026: £50,000 to £300,000 for One High-Risk Development Step Toward a New Medicine, Device, or Diagnostic — Applications Close 11 November 2026

There is a specific, well-known dead zone in UK medical translation. You have a concept. You have some data supporting it. You are nowhere near ready for a multi-million-pound Proof of Concept award, because one particular question — will the vector work, will the assay hold up, will the prototype survive contact with a real user — has not been answered yet. Until it is answered, no serious funder will commit, and until a funder commits, nobody will pay to answer it.

The MRC Impact Acceleration Award exists to buy exactly that one answer. It opened on 16 July 2026 and closes at 4:00pm UK time on 11 November 2026. The award range is £50,000 to £300,000 full economic cost, over six to 18 months, and MRC funds 80% of FEC plus 100% of permitted exceptions.

This opportunity was previously called “Gap Fund: single-step support for medical product development.” If you searched for that name and found nothing, this is the scheme you were looking for.

Key details at a glance

Two further rounds are already scheduled on the published timeline: one open from 12 November 2026 to 10 March 2027, and another from 11 March 2027 to 14 July 2027. If November is too soon for you, the scheme is a recurring one worth calendaring rather than a one-off.

What the award actually funds

MRC is explicit that this scheme sits in a defined position in its translational ladder. Below it sits the MRC Impact Acceleration Account (IAA) — small-scale pump-priming money held institutionally. Above it sits MRC Proof of Concept, formerly the Developmental Pathway Funding Scheme (DPFS), which handles substantial, multi-stage packages including pre-clinical safety and toxicology and early-phase clinical trials. The Impact Acceleration Award bridges the two.

The eligible product categories are broad. MRC lists new small molecule medicines; vaccines for infectious and non-infectious disease; biologics including antibodies, peptides and proteins; advanced therapeutics such as gene, cell, RNA, nucleic acid and T-cell therapy; complex medicines including PROTACs, molecular glues and antibody-drug conjugates; regenerative medicine; repurposing of existing therapies for new indications; medical devices; digital healthcare and app development; diagnostics including biomarker validation; medical imaging technology; surgical techniques and tools; behavioural and psychological interventions; and radiotherapy and radiation protocols.

All human diseases and medical interventions are in scope, in both UK healthcare and global health contexts.

Example activities MRC gives include high-risk elements of therapeutic discovery, quantification and validation; high-risk stages of prototype development; early prototype testing; initial biomarker validation; vector identification or optimisation; and hit expansion medicinal chemistry.

Note the boundary drawn around diagnostics: biomarker validation is supported, biomarker identification is not. That distinction is characteristic of the whole scheme. You are being funded to test something, not to find something.

The single-step rule is the scheme, not a formality

Most rejected applications to this fund fail on one point, and MRC says so plainly in more than one section of the guidance: applications that involve multiple work packages are on the explicit “will not support” list, and the panel states that projects with multiple goals and work packages that do not address a single high-risk evidence gap are “unlikely to be supportable.”

MRC also warns against structuring your project like a short grant application. That is a useful reframe. A research grant answers a question by assembling several strands of evidence. An Impact Acceleration Award answers one binary question about developability, and then stops.

The fund is designed around this. Projects will not be milestoned. There is a light-touch post-award process with a mandatory final report at the end. Requests for change relating to unforeseen scientific developments will not be considered — though changes relating to maternity, paternity, adoption, parental or sick leave are allowed under standard grant conditions. In other words, MRC is trading administrative flexibility for speed and low bureaucracy, on the assumption that a genuinely single-step project should not need renegotiating mid-flight.

MRC also recommends requesting only the funding needed for the specific goal, unless applying for the maximum is scientifically justified. Reaching for £300,000 because it is available is a legible signal that the step is not really one step.

Who is eligible

You must be based at an MRC-eligible UK research organisation, be able to show that you will direct the project and be actively engaged in the work, and be seeking to generate critical preliminary data that builds confidence in a development strategy for a new or repurposed medicine, device, diagnostic test or other medical intervention.

Charities and third sector organisations are not eligible as project lead unless they are approved UKRI Independent Research Organisations, in which case they can lead or co-lead. Businesses cannot lead but can participate as project partners.

International researchers cannot be project lead. They can be included as “project co-lead (international)” where they make a major intellectual contribution to the design or conduct of the project, and that contribution must be explained and justified in the application. MRC Unit The Gambia at LSHTM and the MRC/UVRI and LSHTM Uganda Research Unit are treated as within the eligible set rather than as international organisations.

If you do not hold a contract of employment covering the project duration, your research organisation is confirming, by submitting, that contracts will be extended beyond the project end date and that necessary support — including mentorship and career development for early career researchers — will be provided.

Two hard constraints on demand: you may submit only one application as project lead, and MRC will not accept uninvited resubmissions of applications submitted after 1 April 2026 to MRC, elsewhere in UKRI, or to any other funder. That covers unchanged, minimally revised, and substantially similar applications, and they will be rejected. If you are unsure whether something counts as a resubmission, email [email protected] before you build the application around it.

What sits outside the remit

MRC lists the exclusions carefully, and each one points at a different funding route:

• Fundamental or investigative research not linked to a product development plan — MRC science areas.
• Clinical studies whose main aim is to investigate disease mechanism — MRC Experimental Medicine Panel.
• Generation of preliminary concept data — Impact Acceleration Accounts.
• Pre-clinical safety and toxicology studies — MRC Proof of Concept.
• Early-phase clinical trials — MRC Proof of Concept. Clinical feasibility studies within the cost limits may be considered, but contact the mailbox before submitting.
• Late-phase clinical trials and late-phase global health trials — NIHR Efficacy and Mechanism Evaluation and Health Technology Assessment programmes.
• Interventions aiming to improve NHS service delivery — NIHR.
• Applications the same or similar to ones rejected by other MRC panels in the last 12 months.

On costs, MRC will not fund PhD studentships, publication costs, bridging funding between grants, costs of applying for IP protection such as patent filing, or conference costs. Regular travel between collaborating organisations is also not permitted.

What it will fund: a contribution to project lead and co-lead salary, research and technical staff, consumables, equipment, travel (excluding conferences), data preservation and sharing costs, estates and indirect costs, and public partnership activities including payments to public contributors. International co-lead costs are funded at 100%, but costs for co-leads in high-income countries, India and China must not exceed 30% of total resources requested. There is no cap for co-leads in countries on the OECD DAC List of ODA Recipients.

The IAA question, and why it matters if you do not have one

The application includes a 200-word question asking whether your research organisation holds an MRC Impact Acceleration Account. Contact your research office before answering.

If your organisation does hold one, you must quote the MRC award reference from its offer letter, name the awarded organisation, and explain why your work is better suited to an Impact Acceleration Award than to IAA support. This is a real screening step — the scheme is not meant to be used for projects that fall within IAA scope.

If your organisation does not hold one, say so explicitly (“IAA has not been awarded to [organisation]”), and you may apply as an earlier-stage project. MRC is clear that this is a genuine route: applicants at organisations without an IAA can propose more preliminary studies, scaled to reflect earlier development, and should flag in the application that they are applying for an IAA-like project. The assessment rigour is identical.

Applications with significant use of AI

If AI is a core enabling technology in your project — not an add-on, but a technique that drives capability, automation, decision-making or user experience — there is a compulsory 500-word section. Failing to complete it means rejection.

You must select exactly one category: training a model based on existing data; clinical validation of a model; repurposing existing models into new interventions; collecting new data and building a new model; or other, defined. Then, in 100 words each, justify data sufficiency, methodology suitability, the AI and clinical expertise of the people involved, and your success criteria for demonstrating the project has been de-risked and is ready for the next funding stage.

MRC publishes the common failures for AI applications, which is unusually helpful: insufficient detail on data origin, quantity or quality even where methodology is well described; strong data narrative but weak articulation of methodology and expertise; missing measurable success criteria; and multiple work packages structured like a short grant.

The panel wants concise, high-signal answers here. Full detail belongs in the Approach section.

The application sections and their word limits

Everything is answered in the UKRI Funding Service. Your research office submits; you cannot submit yourself.

• Summary (550 words) — plain English, used to identify assessors, published externally.
• Background to application (600) — must use four headings: background overview, previous funding and funders, resubmission, correspondence with MRC. If previous funding is not relevant, keep the heading and write N/A.
• Fit to funding opportunity (400) — four compulsory questions: your two-to-three-sentence elevator pitch; the single high-risk development step; how completing it prepares you for substantive funding or direct patient benefit; and the potential impact including success criteria. Missing any one means rejection.
• MRC Impact Acceleration Account (200).
• AI section (500, where applicable).
• Your research organisation’s support (200) — a named person, their position and office, an address or web link, and a description of the support offered. Get this approved by your tech transfer or translational research office first.
• Approach (1,500) — development to date, proposed work, the critical endpoint data, risks and mitigations, expertise required, and a workplan with an embedded Gantt chart or equivalent. Include methodology and experimental design, statistical support and analysis plans, sample sizes and power calculations, effect sizes and variability, and sources of bias with mitigation. Animal work follows the MRC embedding diversity in research design policy and the separate animals section.
• Opportunity and market (1,000) — the clinical need, the route to a prototype or product, disease burden or bottleneck addressed, competing solutions and their status, your competitive advantage, and the potential market.
• Applicant and team capability to deliver (2,000) — 1,500 words in Résumé for Research and Innovation module format covering the whole team, plus up to 500 optional words of Additions for context such as career breaks.
• Resources and cost justification (1,200) — staff, significant travel, equipment over £25,000, unusual consumables, facilities, exceptions, public involvement, data costs, international co-lead costs against the 30% cap, NHS research costs, animal costs, and outsourcing. For outsourced work, state scope, relevance, why it cannot be done in-house, why that provider, cost, tendering process, and any conflicts of interest.
• Project partners — each named partner needs a letter or email of support, uploaded as a single PDF in English or Welsh. Anyone in your core team, and any organisation employing a core team member — including other departments of the same organisation — cannot be a project partner. Industry partners trigger the Industry Collaboration Framework section.

Images are permitted where they carry information words cannot, with a captioned legend below each one that counts toward your word limit. Sentences or paragraphs as images, tables as images, or excessive images will get your application rejected.

Generative AI may be used to prepare applications, subject to UKRI’s policy — apply caution.

How the panel decides

Assessment is by members of the MRC Proof of Concept panel, with additional expertise brought in as needed. Notably, no external expert review comments are obtained. There is no reviewer-response stage to rescue an unclear application. What you submit is what gets judged, by generalist-translational experts rather than by specialists in your exact subfield. Write accordingly.

The formal assessment areas are background, approach including data management, applicant and team capability, intellectual property rights, resources and costs, and ethics and responsible research and innovation.

The panel then weighs four things:

1. Clinical or medical need — is the need significant, and does your approach have an advantage over competing solutions?
2. Rationale — how strong is the scientific rationale, and how likely is the proposed solution to meet the need?
3. Deliverability — does the team have the expertise and support, is the project designed to generate the right data to progress, is the future development plan realistic?
4. Intellectual property — is there an appropriate IP strategy to enable downstream development, clinical uptake or commercialisation?

One line in the guidance is worth quoting because it should change how you write: “The panel is keen to support high risk projects, as long as the project plan is designed to enable a clear decision on the suitability of the intervention for onward translation, at the end of this phase of funding.” MRC states that translational projects are inherently risky and that a 50% failure rate is expected across the portfolio.

The panel is not asking you to promise success. It is asking you to promise a clear answer. A project that will definitively show the approach does not work is a good outcome by the scheme’s own logic. A project that might produce ambiguous data either way is not, however promising the underlying science.

Decisions of the Proof of Concept panel are not open to appeal.

Preparation strategy

Start with your research office and tech transfer office, not with the application form. Three things depend on them and none can be produced overnight: whether your organisation holds an MRC IAA and the award reference if so; the named institutional support statement; and confirmation that your organisation is registered on the UKRI Funding Service. If your lead organisation is an NHS body, check availability in the Funding Service early — there may be extra setup steps.

Then write the elevator pitch and the single-step statement before anything else. If you cannot state the step in one sentence without an “and,” you have two steps. Resolve that before you write 1,500 words of Approach around an unresolved scope.

Define your success criteria numerically and early. They appear in Fit to funding opportunity, in Approach as deliverables, and — for AI projects — again in the AI section. Inconsistency across those three is easy for a panel to spot and hard to explain.

Build the IP position in parallel. Because IPR is a named assessment area but patent filing costs are explicitly unfundable, the panel expects a strategy that already exists, not one you propose to develop with the money.

MRC points to several resources worth using while preparing: the MRC Regulatory Support Centre for research involving human participants, tissues or data; the Repurposing Medicines Toolkit developed with LifeArc for drug repurposing projects; supplementary applicant guidance for clinical test development; the NHS Innovation Service; the MRC-LifeArc Innovation Hubs for Gene Therapies Network; and the Nucleic Acid Therapy Accelerator. A webinar for potential applicants held on 16 June 2025 is available to watch on YouTube via the opportunity page.

Finally, work backwards from institutional deadlines, not the UKRI one. Your research office submits the application and can return it to you for editing. Their internal cut-off will be days or weeks before 11 November, and once submitted your application cannot be changed or amended.

Common mistakes to avoid

• Structuring the project as multiple work packages. This is the single most-cited disqualifier.
• Requesting the full £300,000 without scientific justification for that scale.
• Proposing preliminary concept data generation, which belongs to IAA funding.
• Omitting one of the four compulsory Fit questions or the AI section where applicable — both are automatic rejections.
• Exceeding the 80% FEC limit, which causes rejection at initial checks.
• Naming a project partner who is in your core team or employed by a core team organisation.
• Listing more than one project lead, which fails at the checking stage.
• Including conference costs, patent filing costs, publication costs, or PhD studentships.
• Submitting an uninvited resubmission of anything sent to any funder after 1 April 2026.
• Leaving no clear plan for what happens after the award. Projects without a plausible route to market or patient benefit after this funding are unlikely to be supported.

Frequently asked questions

Can I apply twice? Not as project lead. You may submit only one application in that role.

What if my institution has no MRC IAA? You can still apply, at an earlier stage of development, provided you say so explicitly and scale the request accordingly. Rigour of assessment does not change.

Are follow-on applications allowed? In exceptional circumstances, with justification for continued support. MRC’s expectation is that a positive result should instead enable a longer, larger application, potentially to Proof of Concept.

Is there a matched funding requirement? No, beyond the standard 20% FEC. Assessors are explicitly barred from treating institutional matched funding as a basis for recommendations. Third-party project partner contributions, direct or in-kind, are encouraged.

When will I hear? The funding decision meeting is 20–21 January 2027, with outcomes communicated within 10 working days and feedback in eight to 10 weeks after the meeting.

Can I do a clinical feasibility study? Possibly, if it fits within the cost limits — but contact [email protected] before submitting rather than assuming.

Official links and contacts

• Opportunity page and application start: UKRI Translation: MRC Impact Acceleration Awards
• Opportunity-specific questions: [email protected]
• General MRC funding and policy questions: [email protected]
• UKRI Funding Service helpdesk: [email protected], 01793 547490 (Monday to Thursday 8:30am–5:00pm, Friday 8:30am–4:30pm)

Put the council and opportunity name in your email subject line and include your application reference where you have one. Contact your research office first for costings and application advice.

Is this the right fund for you?

Apply if you can name one experiment, one build, or one validation that stands between your existing data and a credible pitch for major translational funding — and if a clean negative result would be genuinely useful to you.

Look elsewhere if your project needs several things to happen in sequence, if you are still identifying rather than validating, if you need safety and toxicology work, or if the honest answer to “what happens after this?” is “we would apply for more of the same.”

The scheme was designed to be agile, low-bureaucracy and quick, run by people who expect half the projects they fund to fail. That is an unusually candid contract, and it rewards applicants who write to it directly rather than dressing a research programme in translational language.